Keep an Eye on ENTB (up nearly 11%)
It's up nearly 11% since the open this morning and it looks to be a strong performer. Trading volume's high, so I'm going to watch for sell-off and profit taking at the end of the day but it's been a good bet for much of last week, and sell-offs yesterday look to have established a new floor below which I don't think it's going fall. ENTB's a strong biotech firm with a kind of lock on certain bioinformatics suites.
The CEO's got a good executive suite in place now, as well, and it's made two outstanding additions to the clinical and research side of the house. With HCR signed into law, I see more research funding flowing into the company's coffers, too. I think, given a bit of time, it can regain it's mid-6 52-week high.
